REFERENCES


• **Baum M, Buzar A, Cuzick J. (2006):** Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidix, Tamoxifen Alone or in combination). Trial efficacy and safety update analys ; (98): 1802-10.


References


• **Dillon M, Mohd Nazri S and Nasir S (2006):** The role of major duct excision and microdochectomy in the detection of breast carcinoma. BMC Cancer. 6: 164.


References


- **Elattar Inas (2005):** Breast cancer magnitude of the problem Egyptian society of surgical Oncology Conference Taba Sini .i:16.


References


- **Geyer FC, Kushner YB, Lambros MB, Natrajan R, Mackay A and Tamber N (2009):** Microglandular adenosis or microglandular adenoma? A molecular


• **Kempson RL and Rouse RV (2006):** Mammary Duct Ectasia – Surgical Pathology Criteria – Stanford University School of Medicine. Stanford CA; 4305-4342.


References

References


References


- **Sarakbi W, Salhab M and Mokbel K (2006):** Does mammary ductoscopy have a role in clinical practice?. International Seminars in Surgical Oncology; 3-16.


• **Solorzano CC, Ahearne PM and Leach SD (2004):** Invasive Breast Cancer, In the M.D. Anderson Surgical
References

Oncology, Edited by Feig BW, Barry DH and Fuhrman GM, 3rd eds; 2: 14-40.


• **VogelVG, CostantinoJP, WickerhamDL(2007):**

  Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA ; 295: 27.

• **Webster J, Piscitelli G and Polli A(1994):** for the Cabergoline Study Group: A comparison of cabergoline and bromocriptine in the treatment of